Press Release – New York, NY – May 6, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, on a registered direct offering of 29,948,334 shares of the Company’s common stock at a public offering price per share of $3.00 without an underwriter or placement agent.
Synergy raised $89.8 million in gross proceeds.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Stephen A. Cohen.
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Lexaria Bioscience Corp. in $2 Million Registered Direct Offering - April 28, 2025
- Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics in $13.8 Million Public Offering - April 28, 2025
- 美国思成律师事务所代表承销商D. Boral Capital完成凤凰亚洲纳斯达克上市 - April 28, 2025
